

**Supplemental Table 1. Comparison of patients with and without previous optic neuritis at baseline.**

	Patients without previous unilateral optic neuritis (average of both eye used for statistical analyses, n=39)	Patients with previous unilateral optic neuritis (only one eye used for statistical analyses, n=21)	p-value
Females <sup>1</sup>	25 (64.1)	14 (71.4)	0.565 <sup>4</sup>
Age at onset <sup>2</sup> (years)	34.0 (12.1)	35.2 (13.4)	0.726 <sup>5</sup>
Disease course			
RMS <sup>1</sup>	33 (84.6)	20 (95.2)	0.222 <sup>4</sup>
SPMS <sup>1</sup>	6 (15.4)	1 (4.8)	
MS disease duration <sup>2</sup> (years)	5.9 (8.0)	7.0 (9.1)	0.630 <sup>5</sup>
ARR at baseline <sup>2</sup>	0.64 (0.79)	0.71 (0.81)	0.747 <sup>5</sup>
EDSS at baseline <sup>3</sup>	1.0 (0 - 6.0)	1.0 (0 - 6.5)	0.765 <sup>6</sup>
DMT at baseline			
Any DMT <sup>1</sup>	25 (64.1)	12 (60.0)	0.758 <sup>4</sup>
Number of previous DMTs <sup>3</sup>	0 (0 - 3)	0 (0 - 3)	0.813 <sup>6</sup>
Interferon beta <sup>1</sup>	1 (2.6)	1 (4.8)	0.262 <sup>4</sup>
Glatiramer acetate <sup>1</sup>	5 (12.8)	4 (19.1)	
Dimethyl fumarate	5 (12.8)	2 (9.5)	
Fingolimod <sup>1</sup>	8 (20.5)	4 (19.1)	
Alemtuzumab <sup>1</sup>	1 (2.6)	0 (0)	
antiCD20-Mabs <sup>1</sup>	5 (12.8)	1 (4.8)	

**Notes:** <sup>1</sup>absolute number (percentage). <sup>2</sup>mean and standard deviation. <sup>3</sup>median and range. <sup>4</sup>chi-square test <sup>5</sup>t-test. <sup>6</sup>Mann-Whitney-U test.

**Abbreviations:** antiCD20-Mabs, anti-cluster-of-differentiation-20-monoclonal antibodies (ocrelizumab, rituximab, ofatumumab); ARR, annualized relapse rate; CEL, contrast-enhancing lesions; DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; RMS, relapsing MS; SPMS, secondary progressive MS.

**Supplemental Figure 1. Risk of disability worsening according to GCIPL below or above 70µm at baseline.**

**Notes:** HR and 95% confidence intervals calculated by multivariate Cox regression models adjusting for sex, age, disease course, disease duration, EDSS at baseline and DMT status.

Number of patients at risk: baseline: 60; year 1: 52; year 2: 33; year 3: 19; year 4: 13; year 5: 7.

**Abbreviations:** DMT, disease-modifying treatment; EDSS, expanded disability status scale; GCIPL, ganglion cell and inner plexiform layer; HR, hazard ratio.

